We are an early-stage biotech company aiming to combat (emerging) viral infectious diseases with a high unmet medical need via protease inhibition. With our proprietary technology platform, we are actively developing novel antiviral drugs that inhibit proteases and block viral replication. We aim for orally administered drugs able to treat in epidemic and pandemic situations.
Our Journey of Developing Broad-Spectrum Antivirals
Tune in to our podcast to learn more: